Moreover, it has been reported that inhibiting SLC1A5 can promote the degradation of epidermal growth factor through the UPS pathway and reduce the expression of epidermal growth factor in the nucleus to help improve the sensitivity of drugs to tumor treatment [105]. This evidence concerns the gene EGF and neoplasm.